Guggulsterone induces apoptosis and inhibits lysosomal-dependent migration in human bladder cancer cells.


Journal

Phytomedicine : international journal of phytotherapy and phytopharmacology
ISSN: 1618-095X
Titre abrégé: Phytomedicine
Pays: Germany
ID NLM: 9438794

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 02 01 2021
revised: 18 04 2021
accepted: 27 04 2021
pubmed: 28 5 2021
medline: 7 7 2021
entrez: 27 5 2021
Statut: ppublish

Résumé

The survival rate and therapeutic options for patients with bladder cancer have improved little in recent decades. Guggulsterone (GS), a phytoestrogen, has been investigated as an anticancer drug in various malignancies. The present study aimed to evaluate the anticancer effects of E-isomer and Z-isomer GS in the human bladder cancer cell lines TSGH8301 (low-grade) and T24 (high-grade) and their underlying mechanisms. The cell survival effect of GS was investigated by the MTT and colony formation assays in bladder cancer cell lines. Flow cytometry was used to analyze the cell cycle and cell death. Migration ability was measured by wound healing and transwell assays. Protein expression was determined by Western blot after GS treatment. The potency of GS on subcutaneous TSGH8301 bladder tumors was evaluated using an in vivo imaging system. E-isomer GS reduced the survival rate of both low- and high-grade human bladder cancer cells. GS caused cell cycle arrest, accompanied by the decrease and increase in cyclin A and p21 levels, respectively. Additionally, caspase-dependent apoptosis was observed following GS treatment. Furthermore, GS treatment downregulated mTOR-Akt signaling and induced autophagy with p62 and LC3β-II expression. Moreover, the farnesoid X receptor was involved in GS-inhibited cell growth. In addition, GS reduced the migration ability with a decrease in integrin-focal adhesion kinase and myosin light chain. Interestingly, the suppression of GS-mediated migration was prevented by the lysosomal inhibitor ammonium chloride (NH The current findings suggest that GS treatment may serve as a potential anticancer therapy for different grades of urothelial carcinoma.

Sections du résumé

BACKGROUND BACKGROUND
The survival rate and therapeutic options for patients with bladder cancer have improved little in recent decades. Guggulsterone (GS), a phytoestrogen, has been investigated as an anticancer drug in various malignancies.
PURPOSE OBJECTIVE
The present study aimed to evaluate the anticancer effects of E-isomer and Z-isomer GS in the human bladder cancer cell lines TSGH8301 (low-grade) and T24 (high-grade) and their underlying mechanisms.
METHODS METHODS
The cell survival effect of GS was investigated by the MTT and colony formation assays in bladder cancer cell lines. Flow cytometry was used to analyze the cell cycle and cell death. Migration ability was measured by wound healing and transwell assays. Protein expression was determined by Western blot after GS treatment. The potency of GS on subcutaneous TSGH8301 bladder tumors was evaluated using an in vivo imaging system.
RESULTS RESULTS
E-isomer GS reduced the survival rate of both low- and high-grade human bladder cancer cells. GS caused cell cycle arrest, accompanied by the decrease and increase in cyclin A and p21 levels, respectively. Additionally, caspase-dependent apoptosis was observed following GS treatment. Furthermore, GS treatment downregulated mTOR-Akt signaling and induced autophagy with p62 and LC3β-II expression. Moreover, the farnesoid X receptor was involved in GS-inhibited cell growth. In addition, GS reduced the migration ability with a decrease in integrin-focal adhesion kinase and myosin light chain. Interestingly, the suppression of GS-mediated migration was prevented by the lysosomal inhibitor ammonium chloride (NH
CONCLUSIONS CONCLUSIONS
The current findings suggest that GS treatment may serve as a potential anticancer therapy for different grades of urothelial carcinoma.

Identifiants

pubmed: 34044254
pii: S0944-7113(21)00129-X
doi: 10.1016/j.phymed.2021.153587
pii:
doi:

Substances chimiques

Antineoplastic Agents, Phytogenic 0
Pregnenediones 0
pregna-4,17-diene-3,16-dione A4PW148END
MTOR protein, human EC 2.7.1.1
TOR Serine-Threonine Kinases EC 2.7.11.1
CASP3 protein, human EC 3.4.22.-
Caspase 3 EC 3.4.22.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153587

Informations de copyright

Copyright © 2021. Published by Elsevier GmbH.

Auteurs

Ying Chen (Y)

Department of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan.

Hisao-Hsien Wang (HH)

Department of Urology, Cheng Hsin General Hospital, Taipei, Taiwan.

Hsin-Han Chang (HH)

Department of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan.

Yun-Hsuan Huang (YH)

Department of Medicine, National Defense Medical Center, Taipei, Taiwan.

Jeffrey R Wang (JR)

Department of Medicine, National Defense Medical Center, Taipei, Taiwan.

Chih-Ying Changchien (CY)

Department of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan; Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

Sheng-Tang Wu (ST)

Division of Urology, Department of Surgery, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan; Department of Medical Planning, Medical Affairs Bureau Ministry of National Defense Taiwan. Electronic address: doc20283@mail.ndmctsgh.edu.tw.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH